Valeant Pharmaceuticals Reaches New 12-Month High at $115.39 (VRX)
Valeant Pharmaceuticals (NYSE:VRX)’s share price reached a new 52-week high during trading hours on Monday, American Banking and Market News reports. The company traded as high as $115.39 and last traded at $112.10, with a volume of 869,362 shares traded. The stock had previously closed at $113.02.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Valeant Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, October 8th. They now have a $112.40 price target on the stock. Separately, analysts at CRT Capital raised their price target on shares of Valeant Pharmaceuticals from $110.00 to $130.00 in a research note to investors on Monday, October 7th. They now have a “buy” rating on the stock. Finally, analysts at BMO Capital Markets set a $123.00 price target on shares of Valeant Pharmaceuticals in a research note to investors on Wednesday, October 2nd. One equities research analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $114.49.
Valeant Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $113.79. The stock’s 50-day moving average is $105.0 and its 200-day moving average is $90.35. The company’s market cap is $37.455 billion.
Valeant Pharmaceuticals (NYSE:VRX) last released its earnings data on Wednesday, August 7th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.06. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $820.09 million. During the same quarter in the previous year, the company posted $1.01 earnings per share. The company’s revenue for the quarter was up 33.6% on a year-over-year basis.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.